Integra LifeSciences forecasts 2026 adjusted EPS of $2.30-$2.40
IART•Integra LifeSciences forecast 2026 revenue of $1.63 billion-$1.65 billion and adjusted EPS of $2.30-$2.40, with organic revenue growth of -0.3% to 0.9%. It projected fourth-quarter revenue of $413 million-$433 million and said Cincinnati flood disruption would reduce quarterly revenue by $15 million-$20 million.
1. 2026 outlook
Integra LifeSciences updated its 2026 revenue outlook to $1.63 billion-$1.65 billion and forecast adjusted earnings of $2.30-$2.40 per share. Organic revenue growth is expected to range from -0.3% to 0.9%.
2. Fourth-quarter projections
The company projected fourth-quarter revenue of $413 million-$433 million and adjusted earnings of $0.61-$0.71 per share. Cincinnati flood disruption is expected to reduce quarterly revenue by $15 million-$20 million, primarily affecting Neurosurgery.
3. Margins and EBITDA
Full-year adjusted gross margins and adjusted EBITDA are expected to remain flat versus 2025, reflecting unfavorable mix and Cincinnati impacts.
